ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1556

The Medication Information-Seeking Behaviors of Rheumatoid Arthritis Patients Who Are Prescribed a New DMARD

Delesha Carpenter1, Lorie Geryk2, Courtney Arrindell3, Beth Jonas4 and Susan J. Blalock5, 1Division of Pharmaceutical Outcomes and Policy, University of North Carolina Eshelman School of Pharmacy, Asheville, NC, 2Division of Pharmaceutical Outcomes and Policy, University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC, 3University of North Carolina at Chapel Hill, Chapel Hill, NC, 4Thurston Arthritis Research Ct, UNC-Chapel Hill, Chapel Hill, NC, 5School of Pharmacy, UNC at Chapel Hill, Chapel Hill, NC

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Compliance, medication, medication side effects and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 9, 2015

Title: Rheumatoid Arthritis - Clinical Aspects Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

We present preliminary longitudinal data about the information-seeking behaviors and medication experiences of RA patients who are prescribed a new DMARD.

Methods: We recruited a convenience sample of 32 adult English-speaking RA patients who were prescribed a new self-administered DMARD from one rheumatology clinic in a southeastern state. At the office visit during which the new DMARD was prescribed, patients reported demographic characteristics and satisfaction with DMARD information provided by their rheumatologist (alpha=0.89). Patients then used a 1-week medication diary to document their experiences with side effects. Patients also completed a 1-week and 1-month follow-up telephone interview during which they reported their use of 15 DMARD information sources, whether their DMARD prescription had been filled, and their medication adherence (8-item Morisky Medication Adherence Scale). We calculated descriptive statistics to describe the sources of DMARD information that patients consulted most often. We examined bivariate associations to determine correlates of DMARD information-seeking and ran a linear regression to examine whether information-seeking predicted DMARD adherence at 1-month follow-up. The regression controlled for patient age, gender, race, reading level, disease duration, and whether DMARD side effects had been experienced (yes/no).

Results: Participants were primarily women (91%) and white (70%). The mean age and disease duration were 48.3 (SD=14.1) and 9.4 years (SD=9.4), respectively. Only 3 (10%) of patients were not satisfied with the DMARD information provided by their rheumatologist. Within 1 week of their office visit, 88% of patients had sought DMARD information; most commonly from brochures/pamphlets (57%), medication package inserts (55%), and the Internet (47%). Patients who experienced side effects sought more information (t(26) =2.27, p<0.05) and older patients sought less information (r=-0.42, p<0.05).  Between 1-week and 1-month follow-up, 73% of patients sought additional DMARD information. At 1-month follow-up, 10 patients still had not filled their DMARD prescription, primarily due to lack of insurance approval or cost. Patients who sought greater amounts of information were less adherent (beta=-0.78, p<0.001).

Conclusion: Most RA patients seek information about their DMARDS. Information-seeking is influenced by demographic characteristics and their experience with side effects. Patients who sought more information were less adherent.


Disclosure: D. Carpenter, None; L. Geryk, None; C. Arrindell, None; B. Jonas, None; S. J. Blalock, None.

To cite this abstract in AMA style:

Carpenter D, Geryk L, Arrindell C, Jonas B, Blalock SJ. The Medication Information-Seeking Behaviors of Rheumatoid Arthritis Patients Who Are Prescribed a New DMARD [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/the-medication-information-seeking-behaviors-of-rheumatoid-arthritis-patients-who-are-prescribed-a-new-dmard/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-medication-information-seeking-behaviors-of-rheumatoid-arthritis-patients-who-are-prescribed-a-new-dmard/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology